Sofinnova Venture Partners IX, L.P. 3
3 · Galera Therapeutics, Inc. · Filed Nov 6, 2019
Insider Transaction Report
Form 3
Sofinnova Venture Partners IX, L.P.
10% Owner
Holdings
Series B-2 Preferred Stock
→ Common Stock (1,797,843 underlying)Series C Preferred Stock
→ Common Stock (535,869 underlying)
Footnotes (2)
- [F1]The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such person's pecuniary interest therein.
- [F2]Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock on a 0.197763-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.